Market Insights
The report titled “Intraosseous Devices Market: Growth, Future Prospects, and Competitive Analysis, 2016–2023” offers strategic insights into the overall intraosseous devices market, along with the market size and estimates for the duration of 2013–2023. The said research study covers an in-depth analysis of multiple market segments based on the type of product, technology, and different geographies.
Intraosseous infusion, a technique for vascular entry, was described initially in 1922 and was widely applied for drug administration in children and adults in the 1940s. It fell out of favor during the 1950s and 1960s when disposable intravenous catheters were developed and techniques for insertion improved. Intraosseous (I.O.) infusion is possible because of the presence of veins that drain the medullary sinuses in the bone marrow of long bones. I.O. is the procedure of injecting fluids or medication into the bone marrow to provide a continuous point of entry into the systemic circulation. This technique is used to provide fluids and medication when intravenous access is not available or feasible. Several different commercially available intraosseous cannulation devices are available, such as manual I.O. needles, semi-automatic devices, battery-powered needles, and impact-driven devices.
The primary anatomic locations for intraosseous infusion include the proximal tibia, distal femur, distal tibia or fibula, proximal humerus, and manubrium. Post the decline in demand after World War II, the market for I.O. devices has gradually picked up as the devices have acquired a foothold in mainstream medicine and emergency response algorithms. The majority of I.O. devices are indicated for use in both adult and pediatric patients and are indicated when vascular access is difficult to obtain, particularly in emergencies or medically necessary cases. The major driver for the intraosseous devices market is the development of rapid and easy-to-use intraosseous placement.
In 2015, EZ-IO devices held the largest market share in the global intraosseous devices market. The device has a simple procedure for emergency medical professionals, with a success rate reaching up to 97%. The device has a comparatively lower infection rate. The devices can be inserted in the proximal humerus, proximal tibia, and distal tibia. FAST1 is specifically designed to be used whenever traditional intravenous access fails.
The success rates for I.O. infusion are as high as or higher than those for traditional IV infusion. Additionally, I.O. infusion is an accepted standard of care and treatment modality. It is endorsed by the American Heart Association, Advanced Trauma Life Support, and Advanced Cardiac Life Support courses, as well as the European Resuscitation Council.
North America was observed as the leading geographical region in the intraosseous devices market due to the rising application of I.O. devices in ambulatory and emergency cases, the increasing prevalence of various chronic diseases, the mounting number of traumatic surgeries, and high military consumption, especially in cases of war. Market experts suggest that I.O. infusion is a rapid, safe, and effective technology for vascular access through the bone marrow when an intravenous attempt fails to establish vascular access. Asia-Pacific was observed as the most potential intraosseous devices market, with rising adoption of I.O. devices. However, the high price and lack of continual training of medical and nursing staff, and well-defined protocols regarding proper handling of the device are restricting the market in this region.
The intraosseous devices market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Pyng Medical Corporation, PerSys Medical, Aero Healthcare, Vidacare/Teleflex, Becton Dickinson Company, Carefusion Inc., and Cook Medical Inc.
Based on the type of product, the global intraosseous devices market is segmented as follows:
- Dieckmann Modified Needle
- Jamshidi Needle
- FAST1 Device
- FASTx Device
- Bone Injection Gun (BIG) Devices
- EZ-IO Device
- NIO Device
Intraosseous infusion (I.O.) is the process of drug delivery that is carried out directly into the bone marrow to provide an entry point into the systemic venous system. Fluids and medicines are provided through this technique when intravenous access is not available or feasible. Market experts suggest that a comparison study between intramuscular (I.M.), intravenous (IV), and I.O. routes of administration revealed that the I.O. route is evidently better than I.M. and comparable to IV administration, especially in the case of pediatric treatment. During initial resuscitation administration of medications and fluids in adults, demand for I.O. infusions is increasing. I.O. infusion should be implemented in all critical situations when peripheral venous access is not easily obtainable. These devices also carry a few complications that are uncommon and mostly related to prolonged use. The I.O. infusion allows for blood sampling and administration of virtually all types of fluids and medications, including vasopressors, with a bioavailability close to the intravenous route. The EZ-IO devices held the largest market share in the intraosseous devices market by product type. The introduction of automatic intraosseous devices has resulted in the ease of delivery of drugs and medication through the intraosseous route, thus driving the intraosseous devices market over the period of 2016 to 2023.
Based on the type of technology, the intraosseous devices market is segmented into:
- Manual IO Needles
- Battery-Powered Driver
- Impact-Driven Devices
Intraosseous (I.O.) access is considered an efficient first alternative to unsuccessful or delayed peripheral or central intravenous (IV) access in emergency situations. The I.O. technique comprises the placement of a vascular device with the tip of the intraosseous catheter in the bone matrix. The fluids or medications are delivered with the help of this catheter immediately into the systemic circulation through the bone marrow cavity. According to experts, substantiation to guide the preference of an intraosseous (I.O.) insertion device is restricted to observational studies and a few trials that differ according to the location (e.g., pre-hospital, hospital), clinical provider (e.g., paramedic, medic, physician), site of insertion, and age of the patient (pediatric or adult). In order to maximize the chance of successful I.O. cannulation, proper training is essential prior to use, regardless of which intraosseous insertion technique is chosen. Manual IO needles include Jamshidi (Cardinal Health) and the modified Dieckmann (Cook Critical Care). These are widely used in I.O. access procedures due to the presence of a special feature known as a trocar, a short needle length with a handle that provides a resting place for the palm, and an adjustable flange or depth marking to guide placement. In 2015, battery-powered drivers were observed as the largest market segment in the I.O. devices market. EZIO comes with a lithium-ion battery driver and needle sets in three lengths for placement in children and adults.
For the purpose of this study, the global intraosseous devices market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year 2015, North America was observed as the leading geographical region in the intraosseous devices market due to the rising application of I.O. devices in ambulatory and emergency cases, the increasing prevalence of various chronic diseases, the mounting number of traumatic surgeries, and military consumption being observed high, especially in cases of war. Market experts suggest that I.O. infusion is a rapid, safe, and effective technology for vascular access through the bone marrow when an intravenous attempt fails to establish vascular access. The EZ-IO is used by 90% of U.S. advanced life support ambulances and over half of U.S. emergency departments, as well as the U.S. military. However, a report published by Vidacare Corporation suggested that, during the Gulf War, the U.S. military had 13,000 medics and 26,000 combat lifesavers with six and three intraosseous units (EZ-IO), respectively; a total of 160,000 intraosseous devices were expected to be used. Asia-Pacific was observed as the most potential intraosseous devices market, with rising adoption of I.O. devices. Recently, Pyng Medical Corp. announced the expansion of its exclusive dealer network globally, with a significant addition to adding India to the Asia-Pacific markets. Market experts suggest that there is a great demand in India for high-quality medical devices made in North America. Pyng’s dominance in sternal I.O. for deployed U.S. military will be leveraged into the Indian military, EMS, and hospital markets. However, the high price and lack of continual training of medical and nursing staff, and well-defined protocols regarding proper handling of the device are restricting the market in this region.
Based on the type of product, the global intraosseous devices market is segmented as follows:
- Dieckmann Modified Needle
- Jamshidi Needle
- FAST1 Device
- FASTx Device
- Bone Injection Gun (BIG) Devices
- EZ-IO Device
- NIO Device
Intraosseous infusion (IO) is the process of drug delivery that is carried out directly into the bone marrow to provide an entry point into the systemic venous system. Fluids and medicines are provided through this technique when intravenous access is not available or not feasible. Market experts suggest that comparison study between intramuscular (IM), intravenous (IV), and IO routes of administration resulted that the IO route is evidently better than IM and comparable to IV administration especially in case of pediatric treatment. During initial resuscitation administration of medications and fluids in adults demand for IO infusion are increasing.
IO infusion should be implemented in all critical situations when peripheral venous access is not easily obtainable. These devices also carry a few complications that are uncommon and mostly related to prolonged use. The IO infusion allows for blood sampling and administration of virtually all types of fluids and medications including vasopressors, with a bioavailability close to the intravenous route. The EZ-IO devices held the largest market in the intraosseous devices market by product type. The introduction of automatic intraosseous devices has resulted in the ease in the delivery of the drugs and medication through the intraosseous route, thus driving the intraosseous devices market over the period of 2016 to 2023.
